Efficacy of adding once-and thrice-daily voglibose in japanese type 2 diabetic patients treated with alogliptin

Endocrine Journal

Volumn 61, Issue 5, 2014, Pages 447-456

  Takahara, Mitsuyoshi ^a   Shiraiwa, Toshihiko ^b   Katakami, Naoto ^a   Kaneto, Hideaki ^a   Matsuoka, Taka Aki ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shiraiwa Medical Clinic   (Japan)

Author keywords

Alpha glucosidase inhibitor; Dipeptidyl peptidase 4 (DPP 4) inhibitor; Once and thrice daily administration

Indexed keywords

1,5 ANHYDROSORBITOL; ALANINE AMINOTRANSFERASE; ALOGLIPTIN; ASPARTATE AMINOTRANSFERASE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; VOGLIBOSE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INOSITOL; PIPERIDINE DERIVATIVE; URACIL;

ABDOMINAL DISTENSION; ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BORBORYGMUS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTESTINE FUNCTION DISORDER; JAPANESE (PEOPLE); LOOSE FECES; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; STOMACH PAIN; WEIGHT CHANGE; AGED; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; MALE; MIDDLE AGED; PIPERIDINES; TREATMENT OUTCOME; URACIL;

EID: 84901776545     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0466     Document Type: Article

References (58)

1. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D (2006) Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38: 423-428.
2. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49: 2564-2571.
3. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, et al. (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29: 2632-2637.
4. Scott R, Wu M, Sanchez M, Stein P (2007) Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61: 171-180.
5. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S (2007) Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 76: 132-138.
6. Dejager S, Razac S, Foley JE, Schweizer A (2007) Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 39: 218-223.
7. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, et al. (2008) Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79: 291-298.
8. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q (2008) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31: 2315-2317.
9. Shimoda S, Iwashita S, Ichimori S, Matsuo Y, Goto R, et al. (2013) Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J 60: 1207-1214.
10. Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M (2013) Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J 60: 733-742.
11. Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, et al. (2012) Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocr J 59: 1131-1136.
12. Tajiri Y, Tsuruta M, Ohki T, Kato T, Sasaki Y, et al. (2012) Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. Endocr J 59: 197-204.
13. Seino Y, Hiroi S, Hirayama M, Kaku K (2012) Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Invest 3: 517-525.
14. Tanaka T, Goto H, Araki R, Yamamoto M, Tanaka T, et al. (2013) Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides. J Diabetes Invest. doi:10.1111/jdi.12140.
15. Kadowaki T, Tajima N, Odawara M, Nishii M, Taniguchi T, et al. (2013) Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. J Diabetes Invest. doi:10.1111/jdi.12116.
16. Nakamura A, Terauchi Y (2013) Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes. Endocr J 60: 45-49.
17. Iwasaki M, Hoshian F, Tsuji T, Hirose N, Matsumoto T, et al. (2012) Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Invest 3: 464-467.
18. Chung SH, Suh S, Kim MY, Kim SK, Kim HK, et al. (2013) Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin. J Diabetes Invest DOI: 10.1111/jdi.12127.
19. Kozawa J, Kitamura T, Nishizawa H, Yasuda T, Maeda N, et al. (2013) Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance. J Diabetes Invest 4: 190-194.
20. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29: 2638-2643.
21. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28: 1556-1568.
22. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ (2007) Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30: 890-895.
23. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S (2007) Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 9: 166-174.
24. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjornsdottir S, et al. (2008) Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 10: 1047-1056.
25. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q (2009) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 25: 2361-2371.
26. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q (2009) Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 63: 46-55.
27. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q (2009) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 11: 167-176.
28. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K (2011) Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 27 Suppl 3: 21-29.
29. Tajima N, Kadowaki T, Okamoto T, Sato A, Okuyama K, et al. (2013) Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. J Diabetes Invest. doi:10.1111/jdi.12116.
30. Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y (2010) Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 57: 667-672.
31. Kusunoki Y, Katsuno T, Myojin M, Miyakoshi K, Ikawa T, et al. (2013) Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J 60: 431-439.
32. Kurozumi A, Okada Y, Mori H, Arao T, Tanaka Y (2013) Efficacy of α-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring. J Diabetes Invest. doi:10.1111/jdi.12059.
33. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, et al. (2012) Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 49: 225-230.
34. Masuda K, Aoki K, Kamiko K, Takihata M, Ito Y, et al. (2013) Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-aday treatment with alpha-glucosidase inhibitors. Expert Opin Pharmacother 14: 1111-1118.
35. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC (2011) Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab 13: 1020-1027.
36. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA (2008) Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two singledose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 10: 1178-1185.
37. Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P (2011) A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 17: 395-403.
38. Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, et al. (2007) Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. Clin Ther 29: 2374-2384.
39. Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, et al. (2007) Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 9: 724-732.
40. Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelova A, et al. (2009) Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 25: 2887-2894.
41. Kalra S, Plata-Que T, Kumar D, Mumtaz M, Sondergaard F, et al. (2010) Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. Diabetes Res Clin Pract 88: 282-288.
42. Hara T, Nakamura J, Koh N, Sakakibara F, Takeuchi N, et al. (1996) An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 19: 642-647.
43. Yamazaki K, Inoue T, Yasuda N, Sato Y, Nagakura T, et al. (2007) Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice. J Pharmacol Sci 104: 29-38.
44. Moritoh Y, Takeuchi K, Hazama M (2010) Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/ db mice. Diabetes Obes Metab 12: 224-233.
45. Goke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, et al. (1995) Voglibose (AO-128) is an efficient alpha-glu-cosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56: 493-501.
46. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W (1995) Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 30: 892-896.
47. Ranganath L, Norris F, Morgan L, Wright J, Marks V (1998) Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet Med 15: 120-124.
48. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, et al. (1998) Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med 15: 485-491.
49. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4: 329-335.
50. Narita T, Katsuura Y, Sato T, Hosoba M, Fujita H, et al. (2009) Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 26: 187-188.
51. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, et al. (2006) 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29: 1214-1219.
52. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-1379.
53. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, et al. (2009) Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373: 1607-1614.
54. Goodman M, Thurston H and Penman J (2009) Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 41: 368-373.
55. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, et al. (2010) Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 12: 613-622.
56. Davies M, Speight J (2012) Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab 14: 882-892.
57. Ali MK, Feeney P, Hire D, Simmons DL, O'Connor PJ, et al. (2012) Glycaemia and correlates of patient-reported outcomes in ACCORD trial participants. Diabet Med 29: e67-74.
58. Hauber AB, Mohamed AF, Johnson FR, Falvey H (2009) Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucoselowering agents. Diabet Med 26: 416-424.